Identification

Brand Names
Nauzene
Generic Name
Fructose
DrugBank Accession Number
DB04173
Background

Not Available

Type
Small Molecule
Groups
Approved, Experimental
Structure
Thumb
Weight
Average: 180.1559
Monoisotopic: 180.063388116
Chemical Formula
C6H12O6
Synonyms
Not Available

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UMaltoporinNot AvailableEscherichia coli (strain K12)
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Fructosteril (Fresenius) / Levugen (Baxter) / lnulon
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Anti NauseaFructose (1.87 g/5mL) + D-glucose monohydrate (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL)LiquidOralMedicine Shoppe International2008-02-062013-06-09US flag
Anti NauseaFructose (1.87 g/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL)LiquidOralMeijer Distribution1996-08-212017-11-01US flag
Anti NauseaFructose (1.87 g/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL)LiquidOralKroger2000-10-042017-11-01US flag
Anti NauseaFructose (1.87 g/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL)LiquidOralRUGBY LABORATORIES2020-09-09Not applicableUS flag
Anti NauseaFructose (1.87 g/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL)LiquidOralH.E.B.1995-11-222017-09-08US flag
Anti NauseaFructose (1.87 g/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL)LiquidOralCardinal Health2020-07-27Not applicableUS flag
Anti NauseaFructose (1.87 g/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL)LiquidOralRite Aid1996-06-122017-11-04US flag
Anti NauseaFructose (1.87 g/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL)LiquidOralSafeway2007-07-302018-05-15US flag
Anti Nausea LiquidFructose (1.87 g/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL)SolutionOralTopco Associates LLC2018-05-14Not applicableUS flag
Anti Nausea Liquid Cherry FlavorFructose (1.87 g/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL)SolutionOralQUALITY CHOICE (Chain Drug Marketing Association)2019-04-16Not applicableUS flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Anti NauseaFructose (1.87 g/5mL) + D-glucose monohydrate (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL)LiquidOralMedicine Shoppe International2008-02-062013-06-09US flag
Anti NauseaFructose (1.87 g/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL)LiquidOralMeijer Distribution1996-08-212017-11-01US flag
Anti NauseaFructose (1.87 g/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL)LiquidOralRUGBY LABORATORIES2020-09-09Not applicableUS flag
Anti NauseaFructose (1.87 g/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL)LiquidOralKroger2000-10-042017-11-01US flag
Anti NauseaFructose (1.87 g/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL)LiquidOralCardinal Health2020-07-27Not applicableUS flag
Anti NauseaFructose (1.87 g/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL)LiquidOralH.E.B.1995-11-222017-09-08US flag
Anti NauseaFructose (1.87 g/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL)LiquidOralSafeway2007-07-302018-05-15US flag
Anti NauseaFructose (1.87 g/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL)LiquidOralRite Aid1996-06-122017-11-04US flag
Anti Nausea LiquidFructose (1.87 g/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL)SolutionOralTopco Associates LLC2018-05-14Not applicableUS flag
Anti Nausea Liquid Cherry FlavorFructose (1.87 g/5mL) + Dextrose, unspecified form (1.87 g/5mL) + Phosphoric acid (21.5 mg/5mL)SolutionOralQUALITY CHOICE (Chain Drug Marketing Association)2019-04-16Not applicableUS flag

Categories

ATC Codes
V06DC02 — Fructose
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as c-glycosyl compounds. These are glycoside in which a sugar group is bonded through one carbon to another group via a C-glycosidic bond.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
C-glycosyl compounds
Alternative Parents
Pentoses / Tetrahydrofurans / Secondary alcohols / Hemiacetals / Polyols / Oxacyclic compounds / Primary alcohols / Hydrocarbon derivatives
Substituents
Alcohol / Aliphatic heteromonocyclic compound / C-glycosyl compound / Hemiacetal / Hydrocarbon derivative / Monosaccharide / Organoheterocyclic compound / Oxacycle / Pentose monosaccharide / Polyol
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
L-fructofuranose (CHEBI:43703)
Affected organisms
Not Available

Chemical Identifiers

UNII
WR469VI1J3
CAS number
Not Available
InChI Key
RFSUNEUAIZKAJO-AZGQCCRYSA-N
InChI
InChI=1S/C6H12O6/c7-1-3-4(9)5(10)6(11,2-8)12-3/h3-5,7-11H,1-2H2/t3-,4-,5+,6-/m0/s1
IUPAC Name
(2S,3R,4R,5S)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol
SMILES
OC[C@@H]1O[C@@](O)(CO)[C@H](O)[C@H]1O

References

Synthesis Reference

Larry W. Peckous, "Integrated process for producing crystalline fructose and a high-fructose, liquid phase sweetener." U.S. Patent US5656094, issued 0000.

US5656094
General References
Not Available
PubChem Compound
439553
PubChem Substance
46504785
ChemSpider
388644
RxNav
4570
ChEBI
43703
PharmGKB
PA449716
PDBe Ligand
LFR
Wikipedia
Fructose
PDB Entries
1zx5 / 2cgj / 2cgl

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Not Yet RecruitingTreatmentFemale Infertility1
3RecruitingTreatmentFemale Infertility1
2RecruitingSupportive CareFatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD1
2TerminatedTreatmentMalignant Melanoma of Skin1
1CompletedTreatmentColorectal Carcinoma (CRC) / Head and Neck Carcinoma / Metastatic Cancers1
1RecruitingBasic ScienceHypoglycemia; Iatrogenic1
1Unknown StatusTreatmentMalignant Melanoma of Skin1
1, 2CompletedTreatmentBrain and Central Nervous System Tumors / Malignant Melanoma of Skin / Metastatic Cancers1
Not AvailableCompletedTreatmentSickle Cell Anemia1
Not AvailableUnknown StatusBasic SciencePhysiology1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
LiquidOral
SolutionIntravenous
SolutionOral
PowderIntravenous50 mg/1ml
InjectionIntravenous
Injection, solutionIntravenous
Injection, solutionParenteral
Injection, solutionParenteral30 %
Injection, solutionParenteral70 %
Injection, solutionParenteral10 %
Injection, solutionParenteral20 %
Injection, solutionParenteral33 %
Injection, solutionParenteral5 %
Injection, solutionParenteral50 %
SolutionOral750 mg/1
SyrupOral
Tablet, chewableOral
TabletOral
SolutionIntravenous
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1110.0 mg/mLALOGPS
logP-2.4ALOGPS
logP-2.8ChemAxon
logS0.79ALOGPS
pKa (Strongest Acidic)10.28ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area110.38 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity36.36 m3·mol-1ChemAxon
Polarizability16.29 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.6923
Blood Brain Barrier+0.7551
Caco-2 permeable-0.8511
P-glycoprotein substrateNon-substrate0.6415
P-glycoprotein inhibitor INon-inhibitor0.9343
P-glycoprotein inhibitor IINon-inhibitor0.9704
Renal organic cation transporterNon-inhibitor0.8814
CYP450 2C9 substrateNon-substrate0.8519
CYP450 2D6 substrateNon-substrate0.8504
CYP450 3A4 substrateNon-substrate0.6607
CYP450 1A2 substrateNon-inhibitor0.9365
CYP450 2C9 inhibitorNon-inhibitor0.9507
CYP450 2D6 inhibitorNon-inhibitor0.9575
CYP450 2C19 inhibitorNon-inhibitor0.9252
CYP450 3A4 inhibitorNon-inhibitor0.9846
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9767
Ames testNon AMES toxic0.9391
CarcinogenicityNon-carcinogens0.9398
BiodegradationReady biodegradable0.6874
Rat acute toxicity1.0362 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9772
hERG inhibition (predictor II)Non-inhibitor0.9115
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Virus receptor activity
Specific Function
Involved in the transport of maltose and maltodextrins, indispensable for translocation of dextrins containing more than three glucosyl moieties. A hydrophobic path ("greasy slide") of aromatic res...
Gene Name
lamB
Uniprot ID
P02943
Uniprot Name
Maltoporin
Molecular Weight
49912.005 Da

Drug created at June 13, 2005 13:24 / Updated at September 28, 2021 21:54